Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
1
33%
Ph not_applicable
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

recruiting267%
withdrawn133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingnot_applicable

Daratumumab for Late Antibody-Mediated Rejection

NCT07081126
recruitingphase_2

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

NCT06636552
withdrawnphase_1

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

NCT05205252

Clinical Trials (3)

Showing 3 of 3 trials
NCT07081126Not Applicable

Daratumumab for Late Antibody-Mediated Rejection

Recruiting
NCT06636552Phase 2

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

Recruiting
NCT05205252Phase 1

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3